JP2006176498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006176498A5 JP2006176498A5 JP2005335154A JP2005335154A JP2006176498A5 JP 2006176498 A5 JP2006176498 A5 JP 2006176498A5 JP 2005335154 A JP2005335154 A JP 2005335154A JP 2005335154 A JP2005335154 A JP 2005335154A JP 2006176498 A5 JP2006176498 A5 JP 2006176498A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hmg
- coa reductase
- reductase inhibitor
- ubidecarenone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 11
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 11
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 9
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 9
- 229960004747 ubidecarenone Drugs 0.000 claims 9
- 208000013824 Acidemia Diseases 0.000 claims 7
- 208000010444 Acidosis Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 235000021588 free fatty acids Nutrition 0.000 claims 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- 229960001495 pravastatin sodium Drugs 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005335154A JP4896501B2 (ja) | 2004-11-26 | 2005-11-21 | 血中遊離脂肪酸低下作用を有する医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004341493 | 2004-11-26 | ||
| JP2004341493 | 2004-11-26 | ||
| JP2005335154A JP4896501B2 (ja) | 2004-11-26 | 2005-11-21 | 血中遊離脂肪酸低下作用を有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006176498A JP2006176498A (ja) | 2006-07-06 |
| JP2006176498A5 true JP2006176498A5 (enExample) | 2009-01-29 |
| JP4896501B2 JP4896501B2 (ja) | 2012-03-14 |
Family
ID=36730936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005335154A Expired - Fee Related JP4896501B2 (ja) | 2004-11-26 | 2005-11-21 | 血中遊離脂肪酸低下作用を有する医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4896501B2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012096998A (ja) * | 2009-02-27 | 2012-05-24 | Kowa Co | 安定なカプセル製剤及びその製造方法 |
| TWI636783B (zh) * | 2012-04-18 | 2018-10-01 | 友霖生技醫藥股份有限公司 | 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2007983C (en) * | 1989-01-18 | 1996-12-10 | Michael S. Brown | Coenzyme q10 with hmg-coa reductase inhibitors |
| US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
| AUPR177300A0 (en) * | 2000-11-29 | 2000-12-21 | Centre For Molecular Biology And Medicine | Therapeutic methods |
| JP2003081873A (ja) * | 2001-06-28 | 2003-03-19 | Takeda Chem Ind Ltd | 臓器機能障害および臓器不全の予防治療剤 |
| JP2005525401A (ja) * | 2002-04-23 | 2005-08-25 | ニュートリション ２１、インコーポレイテッド | 薬剤誘発インスリン抵抗性を阻害するためのクロム組成物およびその使用方法 |
-
2005
- 2005-11-21 JP JP2005335154A patent/JP4896501B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2022100434A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| JP2010047616A5 (enExample) | ||
| WO2008045170A3 (en) | Statin and omega-3 fatty acids for reduction of apo-b levels | |
| JP2015503588A5 (enExample) | ||
| JP2008509132A5 (enExample) | ||
| JP2004537553A5 (enExample) | ||
| EA200970359A1 (ru) | Статин и омега-3 жирные кислоты для снижения уровней аро-в | |
| AR076835A1 (es) | Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de drogas en dosis elevadas y reducidas. metodo. | |
| NZ552389A (en) | Statin pharmaceutical compositions and related methods of treatment | |
| NZ603207A (en) | Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
| WO2018064654A1 (en) | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof | |
| JP2007238598A5 (enExample) | ||
| JP2005511619A5 (enExample) | ||
| WO2009059717A3 (en) | Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use | |
| JP2008063322A5 (enExample) | ||
| JP2006176498A5 (enExample) | ||
| JP2014521738A5 (enExample) | ||
| JP2013536408A5 (enExample) | ||
| JP2008513379A5 (enExample) | ||
| EP2780002A1 (en) | Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability | |
| JP2005522490A5 (enExample) | ||
| RU2014145102A (ru) | Комбинация | |
| WO2010047559A2 (ko) | 방출성이 제어된 약제학적 제제 | |
| JP2010526152A5 (enExample) | ||
| RU2007148908A (ru) | Составы для снижения риска возникновения вызванной лекарственными средствами аритмии |